In addition to traditional statins, several new lipid-lowering drugs, such as cholesteryl ester-transfer protein inhibition and proprotein convertase subtilisin/kexin type 9, have been recommended [26–30], which have to some extent reduced the mortality rate of IHD. Here, PCSK9 is linked to myocardial ischemia.